/f/125658/7246x3240/f72d1f6fc5/esc-logo-lock-up-red-pos-rgb.png){kind=logo}
Enthusiasm vs. evidence for COVID-19 pharmacotherapies: what do we know and what have we learnt?
Event: ESC Congress 2021 - The Digital Experience
Topic: Cardiovascular Disease in Special Populations
Session type: Official Joint Session
Hot topics in Asia: cardiac care unit, COVID-19 and acute heart failure
Event: ACVC 2021
Topic: Acute Cardiac Care
Session type: Symposium
Paradigm shifts in HFrEF management: SGLT2-Inhibitors
Event: ESC Asia with APSC & AFC 2020
Topic: Chronic Heart Failure
Session type: Industry Technology and Innovation session
Challenging paradigms and changing the course of chronic kidney disease (CKD) The era of SGLT2i
Event: ESC Asia with APSC & AFC 2020
Topic: Renal Failure and Cardiovascular Disease
Session type: Industry Technology and Innovation session
APSC Consensus Statements
Event: ESC Asia with APSC & AFC
Topic: Other
Session type: Special Session
Understanding PCSK9 Inhibitors: what, when and why?
Event: ESC Asia with APSC & AFC
Topic: PCSK9-Antagonists
Session type: Satellite Symposium
Controversies in 2019
Event: ESC Asia with APSC & AFC
Topic: Other
Session type: Debate Session
The burden of cardiovascular diseases in 2020: from angina treatment to optimized care of heart failure
Event: ESC Asia with APSC & AFC
Topic: Other
Session type: Satellite Symposium
Personalized tobacco cessation strategies for your patient: patches, drugs or e-cigarettes?
Event: ESC Congress 2019
Topic: Tobacco
Session type: Symposium
ESC 365 is supported by
